These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 27687622)

  • 1. Statin derivatives as therapeutic agents for castration-resistant prostate cancer.
    Ingersoll MA; Miller DR; Martinez O; Wakefield CB; Hsieh KC; Simha MV; Kao CL; Chen HT; Batra SK; Lin MF
    Cancer Lett; 2016 Dec; 383(1):94-105. PubMed ID: 27687622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Galectin-3 Is Implicated in Tumor Progression and Resistance to Anti-androgen Drug Through Regulation of Androgen Receptor Signaling in Prostate Cancer.
    Dondoo TO; Fukumori T; Daizumoto K; Fukawa T; Kohzuki M; Kowada M; Kusuhara Y; Mori H; Nakatsuji H; Takahashi M; Kanayama HO
    Anticancer Res; 2017 Jan; 37(1):125-134. PubMed ID: 28011482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simvastatin Up-Regulates Annexin A10 That Can Inhibit the Proliferation, Migration, and Invasion in Androgen-Independent Human Prostate Cancer Cells.
    Miyazawa Y; Sekine Y; Kato H; Furuya Y; Koike H; Suzuki K
    Prostate; 2017 Mar; 77(4):337-349. PubMed ID: 27862098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of carmustine and selenite effectively inhibits tumor growth by targeting androgen receptor, androgen receptor-variants, and Akt in preclinical models: New hope for patients with castration resistant prostate cancer.
    Thamilselvan V; Menon M; Thamilselvan S
    Int J Cancer; 2016 Oct; 139(7):1632-47. PubMed ID: 27198552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination therapy with novel androgen receptor antagonists and statin for castration-resistant prostate cancer.
    Nakayama H; Sekine Y; Oka D; Miyazawa Y; Arai S; Koike H; Matsui H; Shibata Y; Suzuki K
    Prostate; 2022 Feb; 82(3):314-322. PubMed ID: 34843630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natural killer cells suppress enzalutamide resistance and cell invasion in the castration resistant prostate cancer via targeting the androgen receptor splicing variant 7 (ARv7).
    Lin SJ; Chou FJ; Li L; Lin CY; Yeh S; Chang C
    Cancer Lett; 2017 Jul; 398():62-69. PubMed ID: 28373004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer.
    Martin SK; Kyprianou N
    Adv Cancer Res; 2015; 127():123-58. PubMed ID: 26093899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reversible lysine-specific demethylase 1 antagonist HCI-2509 inhibits growth and decreases c-MYC in castration- and docetaxel-resistant prostate cancer cells.
    Gupta S; Weston A; Bearrs J; Thode T; Neiss A; Soldi R; Sharma S
    Prostate Cancer Prostatic Dis; 2016 Dec; 19(4):349-357. PubMed ID: 27349498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiproliferative activity of novel imidazopyridine derivatives on castration-resistant human prostate cancer cells.
    Muniyan S; Chou YW; Ingersoll MA; Devine A; Morris M; Odero-Marah VA; Khan SA; Chaney WG; Bu XR; Lin MF
    Cancer Lett; 2014 Oct; 353(1):59-67. PubMed ID: 25050738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BCAR4 activates GLI2 signaling in prostate cancer to contribute to castration resistance.
    Cai Z; Wu Y; Li Y; Ren J; Wang L
    Aging (Albany NY); 2018 Dec; 10(12):3702-3712. PubMed ID: 30513511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A rare castration-resistant progenitor cell population is highly enriched in Pten-null prostate tumours.
    Sackmann Sala L; Boutillon F; Menara G; De Goyon-Pélard A; Leprévost M; Codzamanian J; Lister N; Pencik J; Clark A; Cagnard N; Bole-Feysot C; Moriggl R; Risbridger GP; Taylor RA; Kenner L; Guidotti JE; Goffin V
    J Pathol; 2017 Sep; 243(1):51-64. PubMed ID: 28603917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anticancer efficacy of simvastatin on prostate cancer cells and tumor xenografts is associated with inhibition of Akt and reduced prostate-specific antigen expression.
    Kochuparambil ST; Al-Husein B; Goc A; Soliman S; Somanath PR
    J Pharmacol Exp Ther; 2011 Feb; 336(2):496-505. PubMed ID: 21059805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multifocal Signal Modulation Therapy by Celecoxib: A Strategy for Managing Castration-Resistant Prostate Cancer.
    Benelli R; Barboro P; Costa D; Astigiano S; Barbieri O; Capaia M; Poggi A; Ferrari N
    Int J Mol Sci; 2019 Dec; 20(23):. PubMed ID: 31816863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T-LAK cell-originated protein kinase (TOPK) enhances androgen receptor splice variant (ARv7) and drives androgen-independent growth in prostate cancer.
    Alhawas L; Amin KS; Salla B; Banerjee PP
    Carcinogenesis; 2021 Apr; 42(3):423-435. PubMed ID: 33185682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simultaneous targeting of androgen receptor (AR) and MAPK-interacting kinases (MNKs) by novel retinamides inhibits growth of human prostate cancer cell lines.
    Ramamurthy VP; Ramalingam S; Gediya L; Kwegyir-Afful AK; Njar VC
    Oncotarget; 2015 Feb; 6(5):3195-210. PubMed ID: 25605250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting androgen receptor versus targeting androgens to suppress castration resistant prostate cancer.
    Guo C; Yeh S; Niu Y; Li G; Zheng J; Li L; Chang C
    Cancer Lett; 2017 Jul; 397():133-143. PubMed ID: 28323036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resistance to docetaxel in prostate cancer is associated with androgen receptor activation and loss of KDM5D expression.
    Komura K; Jeong SH; Hinohara K; Qu F; Wang X; Hiraki M; Azuma H; Lee GS; Kantoff PW; Sweeney CJ
    Proc Natl Acad Sci U S A; 2016 May; 113(22):6259-64. PubMed ID: 27185910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PXD101 potentiates hormonal therapy and prevents the onset of castration-resistant phenotype modulating androgen receptor, HSP90, and CRM1 in preclinical models of prostate cancer.
    Gravina GL; Marampon F; Muzi P; Mancini A; Piccolella M; Negri-Cesi P; Motta M; Lenzi A; Di Cesare E; Tombolini V; Jannini EA; Festuccia C
    Endocr Relat Cancer; 2013 Jun; 20(3):321-37. PubMed ID: 23507703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Additive inhibitory effects of simvastatin and enzalutamide on androgen-sensitive LNCaP and VCaP prostate cancer cells.
    Syvälä H; Pennanen P; Bläuer M; Tammela TL; Murtola TJ
    Biochem Biophys Res Commun; 2016 Dec; 481(1-2):46-50. PubMed ID: 27833018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic antitumor effect of NVP-BEZ235 and sunitinib on docetaxel-resistant human castration-resistant prostate cancer cells.
    Park HS; Hong SK; Oh MM; Yoon CY; Jeong SJ; Byun SS; Cheon J; Lee SE; Moon du G
    Anticancer Res; 2014 Jul; 34(7):3457-68. PubMed ID: 24982354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.